BRIDGEBIO PHARMA INC.

BridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)

18 8 2022 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma, Sentynl Therapeutics and Medison Pharma Announce Approval in Israel for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

10 8 2022 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Update

04 8 2022 07:30:01 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial

26 7 2022 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma and Sentynl Therapeutics Receive Positive CHMP Opinion for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A

25 7 2022 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic Diseases

21 7 2022 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Announces Founding Affiliation with Bakar Labs, Incubator at UC Berkeley’s Bakar BioEnginuity Hub

21 7 2022 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers

27 6 2022 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease

22 6 2022 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Shares Positive Phase 2b Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1)

13 6 2022 08:00:01 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Affiliate Venthera Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations

10 6 2022 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference

09 6 2022 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in June Investor Events

06 6 2022 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias

26 5 2022 13:00:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

20 5 2022 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in May Investor Events

17 5 2022 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years

13 5 2022 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology

12 5 2022 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in the Bank of America Securities Healthcare Conference

10 5 2022 16:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update

05 5 2022 07:30:02 提供 Nasdaq GlobeNewswire